Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Psyence Biomedical Ratifies Put Option Deal With PsyLabs to Secure Psychedelic Supply

Tipranks - Tipranks - Sat Feb 14, 3:30PM CST

Valentine's Day Sale - 70% Off

Psyence Biomedical ( (PBM) ) has shared an update.

On February 13, 2026, Psyence Biomedical announced that its board ratified a put option agreement with PsyLabs, allowing PsyLabs to require Psyence to make a future equity investment via a share-for-share exchange at fair market value. The deal sits within a broader strategic relationship, giving Psyence access to PsyLabs’ investigational and commercial-scale manufacturing of pharmaceutical-grade psychedelic compounds.

The structure provides Psyence with a path to potentially acquire a significant stake in PsyLabs while securing predictable, high-quality psychedelic supply for future clinical and commercial programs. By using a put option rather than an immediate cash investment, Psyence preserves near-term financial flexibility and cash for clinical and regulatory execution, although related-party ties prompted a special committee of independent directors to review and ratify the transaction using an external valuation.

More about Psyence Biomedical

Psyence Biomedical Ltd., listed on Nasdaq under the symbol PBM, is a biopharmaceutical company developing nature-derived, non-synthetic psilocybin and ibogaine-based psychedelic medicines. It focuses on evidence-based, FDA-approved treatments targeting unmet mental health needs through a vertically integrated, multi-asset therapeutic platform.

PsyLabs, its strategic partner, is a psychedelic active pharmaceutical ingredient developer licensed to cultivate, extract, and export psilocybin and other compounds to legal medical and research markets. PsyLabs operates an ISO 22000-certified facility, supplying purified psychedelic extracts globally and expanding its pipeline to next-generation psychedelics.

Average Trading Volume: 350,520

Technical Sentiment Signal: Sell

Current Market Cap: $3.03M

Learn more about PBM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).